255 related articles for article (PubMed ID: 33728547)
1. A semi-mechanistic exposure-response model to assess the effects of verinurad, a potent URAT1 inhibitor, on serum and urine uric acid in patients with hyperuricemia-associated diseases.
Leander J; Sunnåker M; Rekić D; Aksenov S; Eriksson UG; Johansson S; Parkinson J
J Pharmacokinet Pharmacodyn; 2021 Aug; 48(4):525-541. PubMed ID: 33728547
[TBL] [Abstract][Full Text] [Related]
2. Dapagliflozin Added to Verinurad Plus Febuxostat Further Reduces Serum Uric Acid in Hyperuricemia: The QUARTZ Study.
Stack AG; Han D; Goldwater R; Johansson S; Dronamraju N; Oscarsson J; Johnsson E; Parkinson J; Erlandsson F
J Clin Endocrinol Metab; 2021 Apr; 106(5):e2347-e2356. PubMed ID: 33075806
[TBL] [Abstract][Full Text] [Related]
3. Discovery of novel verinurad analogs as dual inhibitors of URAT1 and GLUT9 with improved Druggability for the treatment of hyperuricemia.
Zhao Z; Liu J; Kuang P; Luo J; Surineni G; Cen X; Wu T; Cao Y; Zhou P; Pang J; Zhang Q; Chen J
Eur J Med Chem; 2022 Feb; 229():114092. PubMed ID: 34998055
[TBL] [Abstract][Full Text] [Related]
4. Verinurad combined with febuxostat in Japanese adults with gout or asymptomatic hyperuricaemia: a phase 2a, open-label study.
Shiramoto M; Liu S; Shen Z; Yan X; Yamamoto A; Gillen M; Ito Y; Hall J
Rheumatology (Oxford); 2018 Sep; 57(9):1602-1610. PubMed ID: 29868853
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics, Pharmacodynamics, and Tolerability of Concomitant Multiple Dose Administration of Verinurad (RDEA3170) and Allopurinol in Adult Male Subjects With Gout.
Kankam M; Hall J; Gillen M; Yang X; Shen Z; Lee C; Liu S; Miner JN; Walker S; Clauson V; Wilson D; Nguyen M
J Clin Pharmacol; 2018 Sep; 58(9):1214-1222. PubMed ID: 29733447
[TBL] [Abstract][Full Text] [Related]
6. Discovery and characterization of verinurad, a potent and specific inhibitor of URAT1 for the treatment of hyperuricemia and gout.
Tan PK; Liu S; Gunic E; Miner JN
Sci Rep; 2017 Apr; 7(1):665. PubMed ID: 28386072
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics, Pharmacodynamics, and Tolerability of Concomitant Administration of Verinurad and Febuxostat in Healthy Male Volunteers.
Hall J; Gillen M; Yang X; Shen Z
Clin Pharmacol Drug Dev; 2019 Feb; 8(2):179-187. PubMed ID: 29688628
[TBL] [Abstract][Full Text] [Related]
8. Lesinurad: A Review in Hyperuricaemia of Gout.
Deeks ED
Drugs Aging; 2017 May; 34(5):401-410. PubMed ID: 28425024
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics, pharmacodynamics, and tolerability of verinurad, a selective uric acid reabsorption inhibitor, in healthy Japanese and non-Asian male subjects.
Hall J; Gillen M; Liu S; Miner JN; Valdez S; Shen Z; Lee C
Drug Des Devel Ther; 2018; 12():1799-1807. PubMed ID: 29950814
[TBL] [Abstract][Full Text] [Related]
10. Effect of Intensive Urate Lowering With Combined Verinurad and Febuxostat on Albuminuria in Patients With Type 2 Diabetes: A Randomized Trial.
Stack AG; Dronamraju N; Parkinson J; Johansson S; Johnsson E; Erlandsson F; Terkeltaub R
Am J Kidney Dis; 2021 Apr; 77(4):481-489. PubMed ID: 33130235
[TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of verinurad, a selective URAT1 inhibitor, for the treatment of patients with gout and/or asymptomatic hyperuricemia in the United States and Japan: Findings from two phase II trials.
Fitz-Patrick D; Roberson K; Niwa K; Fujimura T; Mori K; Hall J; Yan X; Shen Z; Liu S; Ito Y; Baumgartner S
Mod Rheumatol; 2019 Nov; 29(6):1042-1052. PubMed ID: 30334639
[No Abstract] [Full Text] [Related]
12. Baicalein alleviates hyperuricemia by promoting uric acid excretion and inhibiting xanthine oxidase.
Chen Y; Zhao Z; Li Y; Yang Y; Li L; Jiang Y; Lin C; Cao Y; Zhou P; Tian Y; Wu T; Pang J
Phytomedicine; 2021 Jan; 80():153374. PubMed ID: 33075645
[TBL] [Abstract][Full Text] [Related]
13. Acute kidney injury observed during phase 1 clinical trials of a novel xanthine oxidase/URAT1 dual inhibitor PF-06743649.
Dua P; Gurrell R; Kirby S; Sudworth M; Loudon PT
Clin Rheumatol; 2016 Aug; 35(8):2045-2051. PubMed ID: 27094945
[TBL] [Abstract][Full Text] [Related]
14. Effect of Renal Impairment on the Pharmacokinetics and Pharmacodynamics of Verinurad, a Selective Uric Acid Reabsorption Inhibitor.
Smith WB; Hall J; Berg JK; Kazimir M; Yamamoto A; Walker S; Lee CA; Shen Z; Wilson DM; Zhou D; Gillen M; Marbury TC
Clin Drug Investig; 2018 Aug; 38(8):703-713. PubMed ID: 29949102
[TBL] [Abstract][Full Text] [Related]
15. (E)-2-(4-bromophenyl)-1-(2, 4-dihydroxyphenyl)ethanone oxime is a potential therapeutic agent for treatment of hyperuricemia through its dual inhibitory effects on XOD and URAT1.
Hu Q; Zhou M; Zhu H; Lu G; Zheng D; Li H; Hao K
Biomed Pharmacother; 2017 Feb; 86():88-94. PubMed ID: 27951420
[TBL] [Abstract][Full Text] [Related]
16. Individualized treatment strategies for hyperuricemia informed by a semi-mechanistic exposure-response model of uric acid dynamics.
Aksenov S; Peck CC; Eriksson UG; Stanski DR
Physiol Rep; 2018 Mar; 6(5):. PubMed ID: 29488355
[TBL] [Abstract][Full Text] [Related]
17. Rationale, design, demographics and baseline characteristics of the randomized, controlled, Phase 2b SAPPHIRE study of verinurad plus allopurinol in patients with chronic kidney disease and hyperuricaemia.
Heerspink HJL; Stack AG; Terkeltaub R; Greene TA; Inker LA; Bjursell M; Perl S; Rikte T; Erlandsson F; Perkovic V
Nephrol Dial Transplant; 2022 Jul; 37(8):1461-1471. PubMed ID: 34383954
[TBL] [Abstract][Full Text] [Related]
18. [Effect of total saponin of Dioscorea on chronic hyperuricemia and expression of URAT1 in rats].
Chen GL; Zhu LR; Na S; Li L
Zhongguo Zhong Yao Za Zhi; 2013 Jul; 38(14):2348-53. PubMed ID: 24199570
[TBL] [Abstract][Full Text] [Related]
19. Urate Transporter URAT1 in Hyperuricemia: New Insights from Hyperuricemic Models.
Li X; Yan Z; Tian J; Zhang X; Han H; Ye F
Ann Clin Lab Sci; 2019 Nov; 49(6):756-762. PubMed ID: 31882426
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics, pharmacodynamics, and safety of verinurad with and without allopurinol in healthy Asian, Chinese, and non-Asian participants.
Johansson S; Han D; Hunt T; Björck K; Florica D; Gillen M; Hall J; Erlandsson F
Pharmacol Res Perspect; 2022 Jun; 10(3):e00929. PubMed ID: 35593744
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]